IL-1 and IL-6 inhibition affects the neutralising activity of anti-SARS-CoV-2 antibodies in patients with COVID-19

Lancet Rheumatol. 2021 Dec;3(12):e829-e831. doi: 10.1016/S2665-9913(21)00321-0. Epub 2021 Oct 29.

Authors

Emanuel Della-Torre^{1

2}, Elena Criscuolo³, Marco Lanzillotta^{1

2}, Massimo Locatelli⁴, Nicola Clementi^{1

3}, Nicasio Mancini^{1

3}, Lorenzo Dagna^{1

2}; COVID-BioB study group

Affiliations

¹ Università Vita-Salute San Raffaele, Milan 20132, Italy.
² Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy.
³ Laboratory of Medical Microbiology and Virology, IRCCS San Raffaele Scientific Institute, Milan, Italy.
⁴ Laboratory Medicine Service, IRCCS San Raffaele Scientific Institute, Milan, Italy.

No abstract available